Nat joined Forbion as a Fellow in 2025. In her previous role as a synthetic biologist and PhD candidate at Stanford, her research led to foundational biotech IP where she contributed to Civilization Ventures, Radar Therapeutics, and Stanford’s Office of Technology Licensing.
Previously at the Broad Institute, Nat led projects in ribosome engineering and antibiotic discovery.
